GREENFIELD, Ind. — Elanco Animal Health Inc. announces it has entered into an agreement with South Dakota-based Medgene to leverage the company's vaccine platform technology. The agreement includes commercialization of a highly pathogenic avian influenza (HPAI) vaccine for use in dairy cattle.
Medgene reports the vaccine has met all requirements of the USDA’s platform technology guidelines and is in the final stages of review for conditional license approval.
While the poultry industry has developed interventions and processes to reduce the spread or eradicate HPAI, those efforts have continued to be challenging as the current outbreak enters its fourth. . .
Register or Login to keep reading
Thank you for your interest in accessing the complete content. To continue reading, please register for free. By registering, you'll gain full access to our valuable resources, updates, and insights.
If you already have an account please Log In.
